Please check your internet connection and try again.
# Walethmade Bromide
## Overview
Walethmade bromide is a synthetic anticholinergic agent.
## Primary Indications
Walethmade bromide is primarily indicated for the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms.
## Adult Dosing
* **Parkinson's Disease:** Typically initiated at 2.5 mg to 5 mg orally three times daily. The dose may be gradually increased based on patient response and tolerability.
* **Drug-Induced Extrapyramidal Symptoms:** Typically 2.5 mg to 5 mg orally once to three times daily as needed.
The maximum daily dose should not exceed 15 mg.
## Pediatric Dosing
There is no established pediatric dosing for walethmade bromide.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dosing may need to be reduced. Specific guidance is limited.
* **Renal Impairment:** Use with caution. Dosing may need to be reduced. Specific guidance is limited.
* **Elderly:** Start with lower doses and titrate slowly due to potential increased sensitivity.
## Contraindications
* Known hypersensitivity to walethmade bromide or any component of the formulation.
* Angle-closure glaucoma.
* Myasthenia gravis.
* Ileus or toxic megacolon.
* Prostatic hypertrophy with urinary retention.
* Tachyarrhythmias.
## Adverse Effects
Common adverse effects include dry mouth, blurred vision, constipation, urinary retention, dizziness, drowsiness, confusion, and cognitive impairment. Less common but serious effects include tachycardia, hallucinations, and heat prostration.
## Key Drug Interactions
* **Other Anticholinergics:** Increased risk of anticholinergic side effects (e.g., atropine, scopolamine, some antihistamines, tricyclic antidepressants).
* **CNS Depressants:** Additive sedative effects (e.g., alcohol, benzodiazepines, opioids).
* **Potassium Chloride:** Increased risk of gastrointestinal ulceration and bleeding when taken concurrently, particularly with slow-release potassium chloride formulations.
* **MAO Inhibitors:** May increase anticholinergic effects.
## Monitoring
* Monitor for signs and symptoms of anticholinergic toxicity (e.g., dry mouth, blurred vision, urinary retention, constipation, confusion).
* Assess for improvement in Parkinsonian symptoms or drug-induced extrapyramidal symptoms.
* Monitor bowel function, especially in elderly patients.
* Evaluate for potential cognitive impairment.
## Clinical Pearls
* Gradual dose titration is recommended to minimize side effects.
* Patients should be advised to avoid activities requiring mental alertness until their response to the drug is known.
* Consider non-pharmacologic interventions for constipation (e.g., increased fluid and fiber intake).
* In elderly patients, cognitive side effects can be particularly problematic and may necessitate dose reduction or discontinuation.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Local protocols may influence dosing and management.
